Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT00052364 Completed - Clinical trials for Advanced Adult Primary Liver Cancer

Oxaliplatin in Treating Patients With Liver Cancer

Start date: September 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of oxaliplatin in treating patients who have unresectable, recurrent or metastatic liver cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00047346 Completed - Clinical trials for Advanced Adult Primary Liver Cancer

Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction

Start date: August 2002
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of erlotinib in treating patients who have unresectable liver cancer and liver dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor

NCT ID: NCT00047229 Completed - Liver Cancer Clinical Trials

Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Start date: October 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy such as doxorubicin use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of doxorubicin by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of combining oblimersen with doxorubicin in treating patients who have locally advanced, recurrent, or metastatic hepatocellular carcinoma (liver cancer).

NCT ID: NCT00044512 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

Start date: August 2002
Phase: Phase 2
Study type: Interventional

Evaluate anti-cancer activity (e.g. proportion of patients with confirmed complete response or partial response) in patients with advanced, inoperable biopsy-proven hepatocellular carcinoma.

NCT ID: NCT00041275 Completed - Liver Cancer Clinical Trials

Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Start date: May 2002
Phase: Phase 3
Study type: Interventional

RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using megestrol may fight liver cancer by blocking the uptake of estrogen. It is not yet known if megestrol is an effective treatment for liver cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of megestrol in treating patients who have liver cancer that cannot be removed by surgery.

NCT ID: NCT00040898 Completed - Liver Cancer Clinical Trials

Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed

Start date: January 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: The Chinese herbal medicine Sho-saiko-to contains ingredients that may slow the growth of tumor cells and stimulate a person's immune system to help kill tumor cells. This may be an effective treatment following hepatic artery embolization. PURPOSE: Phase II trial to study the effectiveness of Sho-saiko-to following hepatic artery embolization in treating patients who have liver cancer.

NCT ID: NCT00033462 Completed - Clinical trials for Advanced Adult Primary Liver Cancer

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

Start date: March 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of erlotinib in treating patients who have unresectable liver, bile duct, or gallbladder cancer. Biological therapies such as erlotinib may interfere with the growth of cancer cells and slow the growth of the tumor.

NCT ID: NCT00030498 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Start date: December 2001
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor

NCT ID: NCT00028496 Completed - Clinical trials for Stage IV Breast Cancer

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

Start date: November 2001
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may make tumor cells more sensitive to the vaccine and may kill more tumor cells

NCT ID: NCT00012324 Completed - Liver Cancer Clinical Trials

Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer

Start date: September 2000
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective for liver cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different chemotherapy regimens in treating patients who have recurrent or unresectable liver cancer.